SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
BURNABY, British Columbia, March 01, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2017. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 78824693. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech. For more information, please visit www.xenon-pharma.com.
“Xenon,” the Xenon logo, and “Extreme Genetics” are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact: Jodi Regts Senior Director, Corporate Affairs Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]
